Intermediate risk (10-year risk of death from CVD ≥ 0.5% to < 2%, with no additional risk factors or < 0.5% with presence of 1 or more risk factors (Yusuf et al., 2001; Schedlbauer et al., 2010; Perk et al., 2012) .
• Guidelines published for Europe (Perk et al., 2012) and other countries before 2013 (Hata et al., 2002; Teramoto et al., 2013 ) recommend a treat-togoal paradigm for LDL-C levels; the assumption is that there is a positive association between the LDL-C levels and the risk of cardiovascular (CV) events.
OBJECTIVES
• To perform a focused literature review of the unmet needs in high-risk patients with hyperlipidaemia:
-To review treatment guidelines of various countries and to examine differences among recommended lipoprotein cholesterol (LDL-C) target levels for patients with hyperlipidaemia at high risk for CVD.
-To review observational studies to determine the proportions of high-risk patients who do not achieve targeted LDL-C levels in a real-world setting.
METHODS

Study Identification
• A targeted literature search of the following databases was performed per a prespecified protocol: Medline, Medline In-Process, Embase, BIOSIS, and the Cochrane Library (1 January 2005 to 31 December 2013). Guideline searches were limited to publications in the last 5 years. There were no geographical or language restrictions.
• Internet sources searched to identify guidelines included the Agency for Healthcare Research and Quality's National Guideline Clearing House. Bibliographic lists of recent and relevant systematic literature reviews and health technology assessments were searched for further studies of interest.
Study Selection
• Screening criteria were as follows: • One researcher reviewed studies for eligibility. A second researcher performed a quality check of a random selection of 10% of titles, abstracts, and full-text articles. Discrepancies were resolved; when a consensus was not reached, a third researcher was consulted.
• Exclusion criteria were as follows: sample size of less than 100; familial hypercholesterolaemia studies.
Outcomes
• Data of interest were as follows:
-Guidelines: recommended target LDL-C levels in patients with hyperlipidaemia at high risk of CVD -Observational studies: number of patients with hyperlipidaemia at high risk of CVD who did not achieve target LDL-C levels 
DISCUSSION
• The ESC/EAS guidelines are widely used in European clinical practice and are the main guidelines used in Belgium, Denmark, France, Ireland, Italy, Poland, and Russia.
• Finland, the Netherlands, Norway, Spain, Sweden, Switzerland, the United Kingdom, and South Africa have developed, or are planning to develop, their own guidelines. In these countries, the recommended LDL-C target levels for various risk categories vary slightly from those in the ESC/EAS guidelines. In Asia, most countries refer to the NCEP-ATP-III guidelines.
• The ACC and AHA's latest guidelines do not recommend a target LDL-C level, due to a lack of evidence from clinical trials; rather, they recommend intensive treatment options based on risk assessment and LDL-C levels.
• Some studies suggested that goal attainment was inversely related to baseline CV risk, (Munawar et al., 2013; Wang et al., 2014; Waters et al., 2009 ) although one of the reasons may be due to the target levels being lower for such patients (< 70 mg/dL).
• Patient nonadherence is cited as an issue in patients not achieving LDL-C goals in various countries (Bourgault et al., 2005; Munawar et al., 2013; Michel et al., 2008; Vacanti et al., 2005) . Nonadherence could be due to scarce financial resources (Vacanti et al., 2005) or improper communication between the health care professional and the patient, particularly among elderly patients and those with poor literacy.
CONCLUSIONS
• In patients in high-risk or very high-risk categories, attainment of LDL-C goals is lower, highlighting suboptimal hyperlipidaemia management worldwide.
• Patients in higher CV-risk categories tend to have more stringent LDL-C target levels, which may contribute to failure to achieve target levels.
• Limited evidence suggests that the reasons for not achieving the target LDL-C could be gender, age, comorbidities (e.g., diabetes and CV risk), hypertension, baseline LDL-C and total cholesterol levels, and choice of treatments and their doses. There is still a need to rigorously explore the causes for this failure through primary studies.
• These conclusions suggest several unmet needs: the failure of large numbers of patients to achieve LDL-C targets, reduction of the patients' risk for CVD, and consequent reduction of the occurrence of CV events.
REFERENCES
Please see the handout for a complete reference list. 
CONTACT INFORMATION
Patients not achieving goal (%)
Middle East/Asia Europe US
RESULTS
Search Results
• Searches for guidelines identified 545 records (databases = 533; Internet and hand searches = 12).
-After the initial screening of titles and abstracts (level 1 screening), 82 publications (databases searches = 70; Internet and hand searches = 12) were progressed to level 2 screening.
-From these, 17 guidelines were reviewed.
• Search results for observational studies are summarised in Figure 1 .
Recommended LDL-C Target Levels for High-Risk Patients (Table 1) • LDL-C target levels for high-risk patients varied based on risk and country. The most common target was < 100 mg/dL (< 2.6 mmol/L), recommended by eight different guidelines in Asia. Fourteen treatment guidelines (5 from Europe and 8 from Asia) set specific LDL-C targets for secondary prevention.
• 
Proportion of High-Risk Patients Not Achieving LDL-C Targets
• LDL-C targets used most commonly in studies were the NCEP-ATP guidelines (21), the Canadian Working Group (3), and the ESC (Third Joint European Task Force) (2); others used country-specific guidelines (4), one of which compared LDL-C level achievement by different targets.
• Most studies reported that between 68% and 96% of very high-risk patients did not achieve an LDL-C goal of < 70 mg/dL, as recommended by the NCEP-ATP guidelines (Figure 2) , with the exception of one study conducted in China (16.9%).
• Most studies found that high-risk patients did not achieve a target (61.8%-93.8%) of < 100 mg/dL, as recommended by the NCEP-ATP guidelines ( Figure 3) ; nine studies reported lower proportions (0.0%-47%).
• For patients at moderately high risk, in 10 out of the 16 studies 35.0% to 78.2% did not achieve the NCEP-ATP target goal of < 130 mg/dL; four studies conducted in the United States (US) reported lower proportions of between 6.6% and 24.0%. Similar results were observed in two other studies: Ilerigelen et al. 2007 (12.7%) and Punithavathi et al. 2009 (15.0%) .
• Using the target of < 97 mg/dL (2.5 mmol/L) as recommended by the Canadian Working Group, three studies reported that between 38.0% and 42.3% of high-risk patients did not achieve this goal. Third Joint European Task Force guidelines, as well as guidelines from Brazil, Hungary, and South Africa, recommended < 2.5 mmol/L; and in five studies, 41.7% to 89.7% patients did not achieve this goal.
• Of all of the common comorbidities, patients with concomitant CVD and diabetes seemed the least likely to reach their target LDL-C goals (50%-91.4%). Three studies reported the likelihood of patients with diabetes, CHD, or the concomitant occurrence of both diseases reaching their LDL-C goals (Arafah et al., 2013; Wong et al., 2013; Dänschel et al., 2013) .
